Engineering Glucose-Responsive Nanomaterials for Adaptive Drug Release in Diabetic Obesity Patients
Mukisa Ian Mugaiga
Department of Pharmacology Kampala International University Uganda
Email:mugaiga.mukisa@studwc.kiu.ac.ug
ABSTRACT
Diabetic obesity, the coexistence of obesity with type 2 diabetes mellitus (T2DM), represents a syndemic condition characterized by chronic hyperglycemia, insulin resistance, low-grade inflammation, and profound pharmacokinetic variability. Conventional antidiabetic regimens, including multiple daily insulin injections and oral agents, are often insufficient to maintain tight glycemic control in these patients without increasing the risk of hypoglycemia and weight gain. Glucose-responsive nanomaterials (GRNs) have emerged as a promising strategy to achieve adaptive, self-regulated drug delivery that couples therapeutic release directly to fluctuating blood glucose levels. By integrating molecular glucose sensors with nanoscale carriers, these systems can theoretically sense hyperglycemia, trigger drug release, and attenuate delivery as euglycemia is restored. This review discusses the pathophysiological context of diabetic obesity that motivates GRN design, outlines key engineering principles, and summarizes major classes of glucose-responsive mechanisms, including glucose oxidase-based, phenylboronic acid-based, and glucose-binding protein platforms. We further highlight representative nano-architectures, such as polymeric nanoparticles, liposomes, micelles, hydrogels, and microneedle patches, and consider how they can be tailored for obese patients with altered tissue perfusion and drug distribution. Preclinical studies in obese and diabetic animal models demonstrate promising glucose-regulated insulin release and weight-modulating co-therapies, though clinical translation remains nascent. Finally, we discuss challenges related to biocompatibility, long-term stability, manufacturability, regulatory approval, and equity of access, and outline future directions, including multi-analyte responsive systems, closed-loop integration with digital health, and personalized nanomedicine for diabetic obesity.
Keywords: Glucose-responsive nanomaterials; adaptive drug delivery; diabetic obesity; insulin nanocarriers; microneedle patches
CITE AS: Mukisa Ian Mugaiga (2026). Engineering Glucose-Responsive Nanomaterials for Adaptive Drug Release in Diabetic Obesity Patients. IAA Journal of Scientific Research 13(1):92-101.